US Stocks
US Options
Emerging Asia
GBP Cash Savings
Charts & Tools
Paper Trading
Extended Hours
Overview
Desktop
Wall Street JournalR
RPRX
Royalty Pharma Plc
28.21
-0.03-0.11%After Hours: 28.25 +0.04 +0.14%18:07 09/18 EDT
OPEN/PREV CLOSE28.17/28.24
TODAY RANGE28.14-28.46
VOL1.21M
MARKET CAP16.74B
52 WEEK RANGE25.01-31.66
AVG VOL (3M)2.63M
% TURNOVER0.20%
TURNOVER--
P/E (TTM)18.75
% RANGE1.15%
EPS(TTM)1.504
P/E(FORWARD)7.27
P/B1.956
BVPS14.42
DIVIDEND0.8400
P/S5.35
BETA--
DIV YIELD2.98%
FREE FLOAT MKT CAP13.72B
SHARES OUTSTANDING593.46M
NEXT EARNINGS11/06-11/11
FREE FLOAT486.42M
LOT SIZE1
EX-DIV DATE08/16/2024
News
Press Releases
Financial Reports
Profile
Simply Wall St·12h ago
Royalty Pharma plc's (NASDAQ:RPRX) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?
NASDAQ·09/10 19:18
RPRX Breaks Above 3% Yield Territory
Seeking Alpha·09/10 02:11
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update
Benzinga·09/04 13:09
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Dow Jones·09/03 21:14
Press Release: Royalty Pharma and Ascendis Pharma -2-
Simply Wall St·08/28 10:06
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Seeking Alpha·08/22 07:04
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
NASDAQ·08/16 14:42
First Week of April 2025 Options Trading For Royalty Pharma (RPRX)
Benzinga·08/16 13:28
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Dow Jones·08/14 11:21
Royalty Pharma Price Target Raised to $51.00/Share From $50.00 by Goldman Sachs
Dow Jones·08/14 11:21
Royalty Pharma Is Maintained at Buy by Goldman Sachs
Benzinga·08/14 11:10
Goldman Sachs Maintains Buy on Royalty Pharma, Raises Price Target to $51
Same Industry
Name/Symbol
Change%
Price